14 reports

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • OTC
  • Biomay AG

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Allergy
  • Allergy Immunotherapy
  • Medical Biotechnology
  • OTC
  • Product Initiative

" House dust mite allergy is one of the most common allergies, impacting the quality of life for patients across ages and geographies.

  • Medical Biotechnology
  • OTC
  • United States
  • World
  • Product Initiative

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy Drug
  • Ophthalmic Solution
  • OTC
  • Pharmaceutical
  • Product Initiative

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy Drug
  • Ophthalmic Solution
  • OTC
  • Pharmaceutical
  • Allergy Therapeutics plc

About ## percent of people who have food allergies are allergic to more than one food.

  • OTC
  • Therapy
  • Canada
  • United States
  • Product Initiative

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • OTC
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Antifungal
  • OTC
  • Therapy
  • United States
  • Aldeyra Therapeutics, Inc.

The drug candidate targets P/ neurokinin ## (NK##) receptors.

  • Antifungal
  • OTC
  • United States
  • Product Initiative
  • Helsinn Group

The drug candidate targets P/ neurokinin ## (NK##) receptors.

  • Antifungal
  • OTC
  • United States
  • Product Initiative
  • Helsinn Group

Efficacy was evaluated at Night ## (first drug administration) and after ## weeks of drug administration (Night ##).

  • OTC
  • Therapy
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • OTC
  • Therapy
  • United States
  • SCYNEXIS, Inc.

THE DRUG CANDIDATE IS A MUTANT DERIVATIVE BIRCH POLLEN ALLERGEN BET V ##.

  • Allergy Drug
  • Antifungal
  • OTC
  • Respiratory Disease
  • Product Initiative

CY-## - DRUG PROFILE DORA-## - DRUG PROFILE DRGT-## - DRUG PROFILE DRUG FOR INSOMNIA - DRUG PROFILE DRUGS TO INHIBIT ANGIOTENSIN II RECEPTOR TYPE ## FOR INSOMNIA - DRUG PROFILE EVT-## - DRUG PROFILE Drug Name C

  • OTC
  • Sleep Aid
  • United States
  • World
  • Product Initiative